The regional banking giant has now cleared all regulatory hurdles for its pending all-stock transaction with Veritex Holdings, set to close in 2025.
The semiconductor equipment giant faces significant headwinds as Washington tightens restrictions on technology exports to key Chinese customers.
Market reacts sharply to the newly combined company's strategic pivot from pharmaceuticals to HR technology and a new capital structure.
Zepzelca, in combination with Roche's Tecentriq, is the first approved first-line maintenance therapy for extensive-stage small cell lung cancer.
ProSense cryoablation system gains marketing authorization as the first minimally invasive treatment for low-risk tumors in women over 70.
Agreement with White Lion Capital gives the network solutions provider the right to sell shares, securing access to growth capital.
H.C. Wainwright more than doubles its price target to $7.00, citing growing cost-competitiveness for the green hydrogen industry.
Regulators expedite review for ALTO-101, a novel treatment for cognitive impairment in schizophrenia, a condition with no currently approved therapies.